Healthtech Late Stage Investors & VC Firms
494 firms in this list, with a median first check of $1M. 98 of them lead rounds. Generated from verified public data and updated continuously.
Abbhi Capital
MiamiSeed–Late Stage
Sherpa Healthcare Partners
Grand CaymanSeed–Late Stage
3 people
Worthwhile Industries Campuses
TorontoLate Stage
Arkin Digital Health
Seed–Late Stage
1 person
Massachusetts Capital Resource Co.
BostonGrowth–Late Stage
3 people
Mother Ventures
New YorkSeed–Late Stage
3 people
Norinchukin Capital
TokyoSeed–Late Stage$2M – $333.3M
Flat World Partners
New YorkSeed–Late Stage
5 people
MCI Capital S.A.
WarsawGrowth–Late Stage$27M – $108M
2 people
HealthCare Ventures, LLC
CambridgeSeries A–Late Stage$1M – $20M
1 person
Cathay Health
San FranciscoSeed–Late Stage
3 people
Realist Ventures
DarienSeed–Late Stage$25K – $500K
1 person
Schouten Investments
AmsterdamGrowth–Late Stage
4 people
Shanghai Creation Investment
ShanghaiLate Stage
Hillhouse Investment
SingaporeGrowth–Late Stage
2 people
Tiantu Capital
ShenzhenSeed–Late Stage
4 people
Huangpu River Capital
ShanghaiSeries C–Late Stage
Chesterfield Fund
LondonGrowth–Late Stage
2 people
Joseph Advisory Services
El PasoLate Stage$5M
1 person
Hiventures
BudapestSeed–Late Stage$43.2K – $43.2M
6 people
Hotung Investment Holdings Ltd.
SingaporeSeries A–Late Stage$300K – $1.5M
Crown Predator Holdings
New YorkSeries C–Late Stage
2 people
Frontier Path VC
LondonGrowth–Late Stage
1 person
Boyu Capital
Grand CaymanGrowth–Late Stage
7 people
Related lists
Healthtech Investors & VC Firms (4190)Healthtech Seed Investors & VC Firms (3233)Healthtech Investors & VC Firms in North America (2665)Healthtech Investors & VC Firms in United States (2436)Healthtech Series A Investors & VC Firms (2309)Late Stage Investors & VC Firms (1725)Healthtech Pre-Seed Investors & VC Firms (1468)Healthtech Investors & VC Firms in Europe (1357)Healthtech Growth Investors & VC Firms (1269)Healthtech Investors & VC Firms in Global (1181)
Data sourced from public filings and firms' own websites — see our methodology.

























